Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Asia-Pacific

A fresh wave of deals highlights why investors favour IP firms and why independent outfits may soon have to rethink their strategy
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
Law firms across the world are seemingly united in their reluctance to give juniors a chance, which shouldn’t be the case
Sponsored

Sponsored

  • Sponsored by DEQI Intellectual Property Law Corporation
    Yanling Zhou of Deqi provides an insight into the evaluation report system for patents, used in proceedings relating to utility models and designs
  • Sponsored by Wanhuida Intellectual Property
    Paul Ranjard and Zhu Zhigang of Wanhuida examine the different cases selected by the Supreme Court in 2019, including those involving position trademarks, OEM processes, and prior use
  • Sponsored by Spruson & Ferguson
    Singapore design registrants are able to enjoy greater benefits from March 19 2020 as the city-state has become the 58th member to join the Locarno Agreement, an international agreement on classification of industrial designs.
  • Sponsored by Hanol IP & Law
    As of December 2019, designs of trendy fashion items can be registered within 10 days in Korea.
  • Sponsored by Remfry & Sagar
    C.A. Brijesh and Sakshi Sharma of Remfry & Sagar examine the law on designs in India, detailing the requirements for design protection and assessing the overlap between this form of protection and copyright and trademark law
  • Sponsored by AnJie Law Firm
    In the US-China Phase One trade deal signed on January 15 2020, notable agreements on patents mostly relate to pharmaceutical sectors – Articles 1.10, 1.11 and 1.12. It is possible that these articles may also have implications for other sectors, which remains to be seen in the subsequent implementation. In addition, the provisions on judicial enforcement and procedures should benefit all patent owners. More technical issues such as indirect infringement or changes to the judicial review of invalidation decisions are not addressed. This update provides a brief overview of these key changes.
APAC Jurisdictions